Stringer Andrea M, Gibson Rachel J, Logan Richard M, Bowen Joanne M, Yeoh Ann S-J, Burns Jaimi, Keefe Dorothy M K
Department of Medical Oncology, Royal Adelaide Hospital, North Terrace, Adelaide, SA, Australia.
Exp Biol Med (Maywood). 2007 Jan;232(1):96-106.
The microflora of the gastrointestinal tract (GIT) are a complex ecosystem, performing a number of beneficial functions. Irinotecan causes both early and late diarrhea, the latter possibly caused, in part, by changes in the microflora of the GIT. Female DA rats were given atropine subcutaneously, prior to a single 200 mg/kg intraperitoneal dose of irinotecan. Animals were monitored for diarrhea and killed at 30 and 60 mins, 2, 6, 12, 24, 48, and 72 hrs after chemotherapy administration. Control rats received no treatment. Fecal samples and stomach, jejunum, and colon samples were collected and stored at -70 degrees C until required. Standard microbiological culture techniques were used to grow and isolate the flora. Biochemical tests were used to identify the bacteria. The level of growth was noted for relative comparison between time points and graded accordingly. Early diarrhea was observed in the rats from 2-6 hrs after treatment, after which time the diarrhea resolved. Late onset diarrhea was apparent 72 hrs after treatment. Changes were seen in the flora of the stomach, jejunum, colon and feces. The majority of microflora changes were seen 6, 12, and 24 hrs after treatment, with a relative increase or decrease in the presence of bacteria in comparison with control rats. In some rats bacteria were not observed at all time points, and different bacteria not seen in control animals were identified in rats treated with irinotecan. These changes were observed up to 72 hrs after treatment. In conclusion, irinotecan treatment causes changes in the flora of the stomach, jejunum, colon, and feces of rats and is associated with the development of diarrhea. These changes in flora may have systemic effects and in particular may contribute to the development of chemotherapy-induced mucositis.
胃肠道(GIT)的微生物群是一个复杂的生态系统,具有多种有益功能。伊立替康会引发早期和晚期腹泻,后者可能部分是由胃肠道微生物群的变化所致。对雌性DA大鼠皮下注射阿托品,然后腹腔注射单次剂量为200mg/kg的伊立替康。监测动物的腹泻情况,并在化疗给药后的30分钟和60分钟、2小时、6小时、12小时、24小时、48小时和72小时处死动物。对照大鼠不接受任何处理。收集粪便样本以及胃、空肠和结肠样本,并储存于-70℃直至需要时使用。采用标准微生物培养技术培养和分离菌群。通过生化试验鉴定细菌。记录生长水平以便在不同时间点之间进行相对比较并据此分级。治疗后2至6小时在大鼠中观察到早期腹泻,此后腹泻症状缓解。治疗72小时后出现迟发性腹泻。在胃、空肠、结肠和粪便的菌群中均发现了变化。大部分菌群变化出现在治疗后的6小时、12小时和24小时,与对照大鼠相比,细菌的存在出现相对增加或减少。在一些大鼠中,并非在所有时间点都能观察到细菌,并且在接受伊立替康治疗的大鼠中鉴定出了对照动物中未出现的不同细菌。这些变化在治疗后长达72小时内均可观察到。总之,伊立替康治疗会导致大鼠胃、空肠、结肠和粪便中的菌群发生变化,并与腹泻的发生有关。这些菌群变化可能具有全身影响,尤其可能促使化疗诱导的粘膜炎的发生。